125 related articles for article (PubMed ID: 24151657)
21. [Peptide vaccine treatment for colorectal cancer].
Okuno K
Nihon Rinsho; 2011 Apr; 69 Suppl 3():574-8. PubMed ID: 22214026
[No Abstract] [Full Text] [Related]
22. Unmet need in lung cancer: can vaccines bridge the gap?
Kim J; Raz D; Jablons D
Clin Lung Cancer; 2008 Feb; 9 Suppl 1():S6-12. PubMed ID: 18540529
[TBL] [Abstract][Full Text] [Related]
23. Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer.
Terazaki Y; Yoshiyama K; Matsueda S; Watanabe N; Kawahara A; Naito Y; Suekane S; Komatsu N; Ioji T; Yamada A; Mine T; Terasaki M; Itoh K; Takamori S; Sasada T
Cancer Sci; 2012 Apr; 103(4):638-44. PubMed ID: 22321067
[TBL] [Abstract][Full Text] [Related]
24. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
[TBL] [Abstract][Full Text] [Related]
25. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Holmes JP; Clifton GT; Patil R; Benavides LC; Gates JD; Stojadinovic A; Mittendorf EA; Ponniah S; Peoples GE
Cancer; 2011 Feb; 117(3):463-71. PubMed ID: 20845479
[TBL] [Abstract][Full Text] [Related]
26. Current immunotherapeutic strategies in lung cancer.
Rüttinger D; Hatz RA; Jauch KW; Fox BA
Surg Oncol Clin N Am; 2007 Oct; 16(4):901-18, x. PubMed ID: 18022551
[TBL] [Abstract][Full Text] [Related]
27. [Development of next-generation peptide vaccination therapy].
Tsukahara T; Hirohashi Y; Emori M; Torigoe T
Nihon Rinsho; 2017 Feb; 75(2):270-274. PubMed ID: 30562863
[TBL] [Abstract][Full Text] [Related]
28. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
[TBL] [Abstract][Full Text] [Related]
29. Peptide vaccines against cancer, infectious diseases, and conception.
Naz RK; Dabir P
Front Biosci; 2007 Jan; 12():1833-44. PubMed ID: 17127424
[TBL] [Abstract][Full Text] [Related]
30. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
[TBL] [Abstract][Full Text] [Related]
31. Harnessing the immune system for the treatment of non-small-cell lung cancer.
Brahmer JR
J Clin Oncol; 2013 Mar; 31(8):1021-8. PubMed ID: 23401435
[TBL] [Abstract][Full Text] [Related]
32. Tailor-made renal cell carcinoma vaccines.
Dranoff G
Cancer Cell; 2012 Sep; 22(3):287-9. PubMed ID: 22975372
[TBL] [Abstract][Full Text] [Related]
33. A new era in anticancer peptide vaccines.
Perez SA; von Hofe E; Kallinteris NL; Gritzapis AD; Peoples GE; Papamichail M; Baxevanis CN
Cancer; 2010 May; 116(9):2071-80. PubMed ID: 20187092
[TBL] [Abstract][Full Text] [Related]
34. MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancer.
Sharma S; Srivastava MK; Harris-White M; Lee JM; Dubinett S
Expert Opin Biol Ther; 2011 Aug; 11(8):987-90. PubMed ID: 21711210
[TBL] [Abstract][Full Text] [Related]
35. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.
De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F
Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114
[TBL] [Abstract][Full Text] [Related]
36. [Development of personalized peptide vaccines for advanced cancer patients].
Yamada A
Rinsho Ketsueki; 2005 Jun; 46(6):433-8. PubMed ID: 16447725
[No Abstract] [Full Text] [Related]
37. Active immunotherapy for non-small-cell lung cancer: moving toward a reality.
Perez CA; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1599-605. PubMed ID: 21999133
[TBL] [Abstract][Full Text] [Related]
38. [Progress on the study of ovarian carcinoma vaccine ].
Peng P; Shen J
Zhonghua Fu Chan Ke Za Zhi; 2004 Jul; 39(7):500-2. PubMed ID: 15347482
[No Abstract] [Full Text] [Related]
39. [Peptide-based cancer vaccine therapy for prostate cancer, bladder cancer, and malignant glioma].
Yamada A
Nihon Rinsho; 2011 Sep; 69(9):1657-61. PubMed ID: 21922770
[TBL] [Abstract][Full Text] [Related]
40. Summary of presentations from the 11th targeted therapies for lung cancer meeting: immunotherapy and vaccines for treatment of lung cancer.
Ujhazy P; Carbone D
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1815-7. PubMed ID: 22005542
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
